Triple-negative breast cancer (TNBC) is a major cause of cancer mortality, with distant metastases, particularly to the lungs, presenting a significant clinical challenge. While epigenetic mechanisms like DNA methylation (DNAm) are known to influence TNBC progression, their association with lung metastasis remains underexplored. To address this gap, we analyze epigenomic and transcriptomic profiles from TNBC cells, xenograft models, and patient cohorts. DNAm profiling of primary tumors, lymph nodes, and lung metastases in our xenograft model reveals significant genome-wide hypomethylation in lung lesions, consistent with findings on patient samples from the AURORA US cohort. Promoter-methylation changes are enriched in pathways linked to invasion and proliferation, and transcriptomic integration identifies 22 regulated genes, with outcome effects varying according to the histone chromatin context. In vitro demethylation in TNBC cells partially recapitulates the expression changes of several candidate genes. Beyond promoters, enhancer elements are also dysregulated in lung metastases, potentially affecting the expression of their associated genes. Among others, elevated AK1, TPI1, and ENO1 expression correlates with a higher risk of lung dissemination in primary TNBC tumors. These findings highlight DNAm alterations associated with TNBC lung colonization and identify candidate prognostic markers, emphasizing DNAm reprogramming as a feature of breast-to-lung-metastatic progression.
Trending
- Pelareorep Earns FDA Fast Track Designation in Second-Line Anal Cancer
- FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
- How Center for Cancer and Blood Disorders Is Changing the Future of CAR-T Cancer Therapy | Health Care
- Ascites-derived lipid barrier at the T cell synapse
- Why It’s So Hard to Just Rest and Why We Need to Do It
- Ivonescimab/Chemotherapy Maintains OS Benefit in EGFR-Mutant NSCLC
- Managing Patient Preferences and Expectations in Frontline EGFR-Mutant NSCLC
- Comprehensive Biomarker Testing to Guide Frontline Therapy in EGFR-Mutant NSCLC

